Raymond James Financial Services Advisors, Inc. Mirati Therapeutics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

  • $73.5 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 11, 2019
SELL
$32.0 - $47.43 $173,088 - $256,548
-5,409 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$47.1 - $62.7 $38,151 - $50,787
-810 Reduced 13.02%
5,409 $255,000
Q2 2018

Jul 30, 2018
SELL
$26.05 - $52.4 $34,985 - $70,373
-1,343 Reduced 17.76%
6,219 $307,000
Q1 2018

Apr 16, 2018
SELL
$17.2 - $34.95 $64,740 - $131,551
-3,764 Reduced 33.23%
7,562 $232,000
Q4 2017

Feb 09, 2018
BUY
$12.65 - $19.0 $143,273 - $215,194
11,326
11,326 $207,000

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email